PPAR-gamma Agonists

Hypoglycemic agents that specifically target PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA. They increase tissue sensitivity to the insulin action and are used to treat TYPE 2 DIABETES MELLITUS.

Also Known As:

Networked: 478 relevant articles (52 outcomes, 86 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Drew, Paul D: 10 articles (04/2008 - 03/2002)
2.	Thiemermann, Christoph: 8 articles (08/2010 - 08/2003)
3.	Xu, Jihong: 5 articles (01/2008 - 04/2005)
4.	Bernardo, Antonietta: 4 articles (07/2009 - 01/2006)
5.	Minghetti, Luisa: 4 articles (07/2009 - 01/2006)
6.	Berger, Joel P: 4 articles (08/2008 - 02/2003)
7.	Forst, Thomas: 4 articles (06/2008 - 01/2007)
8.	Pfützner, Andreas: 4 articles (06/2008 - 01/2007)
9.	Kielian, Tammy: 4 articles (04/2008 - 02/2003)
10.	Heneka, Michael T: 4 articles (11/2006 - 03/2004)

Related Diseases

1.	Insulin Resistance 08/01/2009 - "PPAR-gamma agonists may have detrimental cardiovascular effects post angioplasty especially in patients with insulin resistance. " 09/05/2005 - "Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat." 11/01/2000 - "As a PPAR-gamma agonist it alters the expression of a number of genes, resulting in a reduction in insulin resistance. " 08/01/2010 - "Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation." 05/01/2007 - "Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats."
2.	Multiple Sclerosis 01/01/2008 - "The therapeutic potential of PPAR-gamma agonists in the treatment of multiple sclerosis will also be considered." 01/01/2008 - "We and others have previously demonstrated that PPAR-gamma agonists modulate the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). " 02/01/2003 - "PPAR-gamma agonists also ameliorate experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. " 03/01/2004 - "These results suggest that use of RXR specific ligands may be highly effective when combined with PPAR-gamma agonists in the treatment of autoimmune demyelinating diseases such as multiple sclerosis (MS)." 01/01/2006 - "Although most of the evidence comes from in vitro observations, an increasing number of studies in animal models further supports the potential therapeutic use of PPAR-gamma agonists in human brain diseases including multiple sclerosis, Parkinson's disease and Alzheimer's disease."
3.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 03/01/2002 - "Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis." 01/01/2008 - "We and others have previously demonstrated that PPAR-gamma agonists modulate the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). " 02/01/2003 - "PPAR-gamma agonists also ameliorate experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. " 04/01/2005 - "Upon activation, microglia produce molecules including NO and TNF-alpha that can be toxic to CNS cells including myelin-producing oligodendrocytes and neurons, which are compromised in the course of MS. Previously, we and others demonstrated that PPAR-gamma agonists including 15d-PGJ(2) are effective in the treatment of experimental autoimmune encephalomyelitis (EAE), an animal model of MS. PPAR-gamma modulation of EAE may occur, at least in part, by inhibition of microglial cell activation. " 05/01/2001 - "In the present study, we examined whether troglitazone, a selective PPAR-gamma agonists, ameliorated experimental autoimmune encephalomyelitis (EAE) induced by administration of myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 in C57BL/6 mice. "
4.	Type 2 Diabetes Mellitus (MODY) 05/01/2010 - "PPAR-gamma agonists and their role in type 2 diabetes mellitus management." 02/05/2010 - "The cardioprotective effects of PPAR-gamma agonists are critically dependent on its APN stimulatory action, suggesting that under pathological conditions where APN expression is impaired (such as advanced type 2 diabetes), the harmful cardiovascular effects of PPAR-gamma agonists may outweigh its cardioprotective benefits." 01/01/2007 - "Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus." 07/01/2006 - "Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes." 05/01/2006 - "We postulated that in type 2 diabetes, the postprandial phase is a pro-inflammatory state that can be modulated by PPAR-gamma agonists. "
5.	Fibrosis (Cirrhosis) 03/01/2005 - "These studies suggest that the PPAR-gamma agonists may have a specific role in ameliorating the course of progressive tubulointerstitial fibrosis under both normoglycemic and hyperglycemic states." 07/01/2014 - "Combination of a peroxisome proliferator-activated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats." 03/01/2005 - "PPAR-gamma agonists exert anti-inflammatory effects in vitro and inhibit the activation of pancreas stellate cells, implicated in the formation and progression of fibrosis. " 07/01/2020 - "Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis." 05/01/2008 - "PPAR-gamma agonists also inhibit fibrosis in a murine model, even when administration is delayed until after the initial inflammation has largely resolved. "

Related Drugs and Biologics

1.	Rosiglitazone (Avandia)
2.	PPAR gamma
3.	Pioglitazone (Actos)
4.	Peroxisome Proliferator-Activated Receptors (PPAR)
5.	Thiazolidinediones
6.	PPAR alpha
7.	PPAR-gamma Agonists
8.	Angiotensin Receptor Antagonists
9.	Prostaglandins
10.	Ligands

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Peritoneal Dialysis
4.	Glycemic Control
5.	Caloric Restriction